scholarly journals Radiomic Analysis of the Heterogeneous Tumor and Surrounding Parenchyma Based on DCE-MRI Decomposition to Predict HER2 Expression in Breast Cancer

2021 ◽  
Author(s):  
Peng Zhang ◽  
Juan Yan ◽  
Zhongqi Liu ◽  
Xiangsheng Li ◽  
Qianxiang Zhou
Keyword(s):  
Breast Cancer ◽  
Contrast Enhancement ◽  
Cross Validation ◽  
Test Group ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
Enhancement Pattern ◽  
Dce Mri ◽  
Validation Test ◽  
Heterogeneous Tumor

Abstract Background Human epidermal growth factor receptor-2 (HER2) correlates with cancer heterogeneity, and the identification of HER2 expression is invasive immunohistochemistry in the clinic. To determine whether noninvasive predictors of HER2 expression are implied in the dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI).Methods 189/47 breast cancer patients collected from The Cancer Imaging Archive (TCIA) were used as a cross-validation/test group. A convex analysis of mixtures (CAM) was conducted to decompose heterogeneous tissues inside and outside the tumor. Their DCE-MRI images were decomposed into relatively homogeneous subregions with different contrast enhancement patterns. The predictor of HER2 expression was composed of radiomic features acquired from intratumoural or peritumoural subregions. The area under the curve (AUC) of receiver operating characteristic (ROC) was used to assess the predictive power.Results The predictor formed in the undecomposed tumor was used as a baseline for comparison (AUC=0.691±0.072/0.625±0.056 in cross-validation/test group). The intratumoural subregion with a contrast enhancement pattern corresponding to the plateau of signal intensity formed a more robust predictor (AUC=0.816±0.059/0.785±0.067, P=0.0128/0.0389). Peritumoral parenchyma of <20 mm from the tumor margin was also researched (AUC=0.589±0.083/0.524±0.064). The peritumoural subregion with a contrast enhancement pattern corresponding to steady enhancement also formed a helpful predictor compared to the undecomposed parenchyma (AUC=0.702±0.068/0.681±0.042, P=0.0128/0.0389). The best predictor was formed when two predictors from subregions were fused together (AUC=0.851±0.057/0.812±0.045, P=0.0011/0.0397).Conclusions A subregion rather than a heterogeneous tumor itself provided a more accurate predictor of HER2 expression. Radiomic predictors from intratumoural and peritumoural subregions were complementary to each other.

scholarly journals Radiomics Analysis Based on Automatic Image Segmentation of DCE-MRI for Predicting Triple-Negative and Nontriple-Negative Breast Cancer

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Mingming Ma ◽  
Liangyu Gan ◽  
Yuan Jiang ◽  
Naishan Qin ◽  
Changxin Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Image Segmentation ◽  
Cross Validation ◽  
Triple Negative ◽  
Characteristic Curve ◽  
Three Dimensional ◽  
Training Dataset ◽  
Breast Cancer Patients ◽  
Dce Mri ◽  
Model Based

Purpose. To investigate whether quantitative radiomics features extracted from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) could be used to differentiate triple-negative breast cancer (TNBC) and nontriple-negative breast cancer (non-TNBC). Materials and Methods. This retrospective study included DCE-MRI images of 81 breast cancer patients (44 TNBC and 37 non-TNBC) from August 2018 to October 2019. The MR scans were achieved at a 1.5 T MR scanner. For each patient, the largest tumor mass was selected to analyze. Three-dimensional (3D) images of the regions of interest (ROIs) were automatically segmented on the third DCE phase by a deep learning segmentation model; then, the ROIs were checked and revised by 2 radiologists. DCE-MRI radiomics features were extracted from the 3D tumor volume. The patients were randomly divided into training ( N = 57 ) and test ( N = 24 ) cohorts. The machine learning classifier was built in the training dataset, and 5-fold cross-validation was performed on the training cohort to train and validate. The data of the test cohort were used to investigate the predictive power of the radiomics model in predicting TNBC and non-TNBC. The performance of the model was evaluated by the area under receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity. Results. The radiomics model based on 15 features got the best performance. The AUC achieved 0.741 for the cross-validation, and 0.867 for the independent testing cohort. Conclusion. The radiomics model based on automatic image segmentation of DCE-MRI can be used to distinguish TNBC and non-TNBC.

scholarly journals Dynamic contrast enhanced-MRI and diffusion-weighted image as predictors of lymphovascular invasion in node-negative invasive breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Bo Bae Choi
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Lymphovascular Invasion ◽  
Breast Cancer Patients ◽  
Enhancement Pattern ◽  
Node Negative ◽  
Dce Mri ◽  
Contrast Enhanced ◽  
Enhancement Curve ◽  
And Diffusion

Abstract Background Lymphovascular invasion (LVI) is an important risk factor for prognosis of breast cancer and an unfavorable prognostic factor in node-negative invasive breast cancer patients. The purpose of this study was to evaluate the association between LVI and pre-operative features of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) in node-negative invasive breast cancer. Methods Data were collected retrospectively from 132 cases who had undergone pre-operative MRI and had invasive breast carcinoma confirmed on the last surgical pathology report. MRI and DWI data were analyzed for the size of tumor, mass shape, margin, internal enhancement pattern, kinetic enhancement curve, high intratumoral T2-weighted signal intensity, peritumoral edema, DWI rim sign, and apparent diffusion coefficient (ADC) values. We calculated the relationship between presence of LVI and various prognostic factors and MRI features. Results Pathologic tumor size, mass margin, internal enhancement pattern, kinetic enhancement curve, DWI rim sign, and the difference between maximum and minimum ADC were significantly correlated with LVI (p < 0.05). Conclusions We suggest that DCE-MRI with DWI would assist in predicting LVI status in node-negative invasive breast cancer patients.

Predominance of RAD21 and ERBB2 amplification and progesterone receptor positivity in tumors of the right breast support breast cancer lateralization.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12557-e12557
Author(s):  
Zachary Spigelman ◽  
Jo-Ellen Murphy
Keyword(s):  
Breast Cancer ◽  
Progesterone Receptor ◽  
Cancer Patients ◽  
Breast Tumors ◽  
Left Breast ◽  
Breast Cancers ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
The Right ◽  
Chi Square Analysis

e12557 Background: Biologic lateralization broadly impacts breast cancer. Malignancies originating in the left breast compared to the right breast tend to be more frequent, larger and of poorer prognosis. Left breast tumors respond differently to HER2-neu signaling and have lateralized Ki67 expression. In a prior study a right-left asymmetry in the neutrophil/lymphocyte ratio (NLR) of breast cancers was identified (ASCO 2018, e13094). As a follow-up, retrospective analysis of results from comprehensive genomic profiling (CGP) of right and left side breast cancer specimens was performed to determine a potential genomic etiology for the observed NLR lateralization. Methods: Tumors from 43 consecutive breast cancer patients underwent analysis for all classes of genomic alterations by hybrid capture-based CGP (Foundation Medicine). The CGP results from the 25 left- and 18 right-sided breast cancer samples were analyzed along with the histologic grade and status of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. Results: In this cohort of advanced breast cancer patients (stage 3-4), no statistically significant differences in lateralization were identified based on patient age, tumor stage, or frequency of ER or Her2 expression (Table). A predominance of PR positivity (p=0.14 chi square analysis) and amplifications in the ERBB2 (p=0.37) and RAD21 (p=0.08) genes were detected in right side tumors. Conclusions: Together with the prior study, trends in asymmetry based on genomic, pathologic, and immunohistologic differences have been detected in breast cancers, including an increased incidence of ERBB2 and RAD21 amplification in right-side breast tumors in this cohort. The predominance of lower PR positivity in the left breast tumors may be due to preferential hypermethylation, consistent with reports that it mediates biologic lateralization changes, downregulates PR expression, and alters amplification rates. Epigenetic methylation, may contribute to asymmetric breast cancer biology and have implications for therapeutic strategy. Further study is warranted.[Table: see text]

scholarly journals Effect of CD44st and HER2 expression on the postoperative prognosis of breast cancer patients

2019 ◽  
Vol Volume 12 ◽  
pp. 577-585 ◽  
Author(s):  
Dan Dan Chen ◽  
Jun An Ji ◽  
Hai Cui Yan ◽  
Guan Hong Huang ◽  
Xin Jian Fang
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
Postoperative Prognosis

The additional utility of ultrafast MRI on conventional DCE-MRI in evaluating preoperative MRI of breast cancer patients

2020 ◽  
Vol 124 ◽  
pp. 108841 ◽  
Author(s):  
Soo Jeong Lee ◽  
Kyung Hee Ko ◽  
Hae Kyoung Jung ◽  
Ji Eun Koh ◽  
Ah Young Park
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Dce Mri ◽  
Ultrafast Mri

Myocardial HER2 expression with 111In-DTPA-trastuzmab scan in patients shortly after anthracycline treatment

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 3057-3057
Author(s):  
P. J. Perik ◽  
M. N. Lub-De Hooge ◽  
P. L. Jager ◽  
M. A. De Korte ◽  
J. A. Gietema ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Xenograft Model ◽  
Metastatic Breast ◽  
Optimal Timing ◽  
Her2 Overexpression ◽  
Compensatory Mechanism ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Adjuvant Trastuzumab

3057 Background: The monoclonal antibody trastuzumab, apart from antitumor effect, can induce cardiotoxicity, particularly when combined with anthracyclines. Myocardial HER2 upregulation may serve, transiently, as a compensatory mechanism induced by cardiac stress. Previously we showed in a xenograft model that 111In-DTPA-trastuzumab scintigraphy can detect HER2 positive lesions (Br J Pharmacol 2004;143:99–106) but that myocardial 111In-DTPA-trastuzumab uptake was found in only 1 of 17 anthracycline-pretreated HER2-positive metastatic breast cancer patients (ESMO 2004#50). This low number may be related to the long interval between anthracycline administration (median 11 months) and performed scan in these patients. To evaluate whether myocardial HER2 expression is induced by anthracyclines, we performed 111In-DTPA-trastuzumab scans in patients shortly after anthracycline treatment. Methods: Patients who completed 4–6 cycles of anthracycline-based chemotherapy (< 3 weeks after last dose) underwent gammacamera imaging 48 and 96 h after iv administration of 150 MBq 111In-DTPA-trastuzumab (5mg). Results: 10 anthracycline-treated patients, 8 as adjuvant breast cancer treatment and 2 for metastatic sarcoma have been enrolled. Myocardial 111In-DTPA-trastuzumab uptake was observed in 5/10 anthracycline-treated patients who all were without symptomatic cardiac dysfunction. Conclusions: Shortly after completion of anthracycline treatment myocardial HER2 overexpression was detectable in 50% of the patients. This may be a transient phenomenon. 111In-DTPA-trastuzumab scan after anthracycline treatment prior to adjuvant trastuzumab may identify patients more susceptible for trastuzumab-induced cardiotoxicity. This important observation may add to optimal timing of trastuzumab therapy i.e. when HER2/neu expression in the heart is negative (again). [Table: see text]

Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 3088-3088 ◽  
Author(s):  
Kaitlin M. Peace ◽  
Elizabeth Ann Mittendorf ◽  
Sonia A. Perez ◽  
Panagiotis Tzonis ◽  
Nikolaos Fragkiskos Pistamaltzian ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Disease Free Survival ◽  
Phase Iii ◽  
Her2 Expression ◽  
Breast Cancer Patients ◽  
Adjuvant Setting ◽  
Gm Csf ◽  
Significant Difference ◽  
Disease Free

3088 Background: AE37 is a Ii-Key hybrid of the HER2 peptide AE36 (HER2776-790), which stimulates peptide-specific T cells. We have completed the active phase of a prospective, randomized, multi-center, phase II trial of the AE37 vaccine in the adjuvant setting. The primary analysis, performed after a median follow up (f/u) of 25 months (mo), did not show a significant difference in disease free survival (DFS) between vaccinated and control patients (pts). However, demonstrating the efficacy of cancer vaccines may require more time than other therapies, especially in malignancies with relatively late recurrences like breast cancer. Here, we present updated efficacy data after extended f/u in subgroups of pts stratified by clinicopathologic characteristics. Methods: Clinically disease-free, node positive or high-risk node negative pts with any level of HER2 expression were randomized to receive AE37 + GM-CSF (VG) or GM-CSF alone (CG) following standard of care therapy. Pts received 6 monthly intradermal inoculations during the primary vaccine series (PVS) followed by 4 boosters administered every 6 mo. Kaplan Meier and log rank analyses were performed from the time of the first inoculation in pts who completed at least the PVS, according to stage, node status, tumor size, HER2 expression and ER/PR status. Results: There were no clinicopathologic differences between groups in the 298 enrolled pts (VG = 153, CG = 145). The vaccine is safe and well tolerated. After a median f/u of 55 mo, there was a trend toward improved DFS in the VG among stage IIB/III pts (VG, n = 73, DFS 82% vs CG, n = 61, 67%, HR = 0.48, p = 0.06) and those with low HER2 expression (HER2 LE, VG, n = 68, 89% vs CG, n = 66, 51%, HR = 0.47, p = 0.1). Improved DFS in the VG was documented in patients with both stage IIB/III disease and HER2 LE (VG, n = 39, 90% vs CG, n = 38, 32%, HR 0.3, p = 0.02) and triple negative (TNBC) pts (VG, n = 21, 89% vs CG, n = 21, 0%, HR 0.26, p = 0.05). Conclusions: The AE37 vaccine is safe and well tolerated and has statistically significant efficacy in stage IIB/III pts with HER2 LE and in TNBC pts. This justifies further evaluation in a phase III study enrolling stage IIb/III pts not eligible for trastuzumab treatment and the very high risk TNBC group. Clinical trial information: NCT00524277.

Sign in / Sign up

Export Citation Format

Share Document